{
    "eid": "2-s2.0-85029152634",
    "title": "Sustained immunogenicity of 2-dose human papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9-14 years: A randomized trial",
    "cover-date": "2017-06-01",
    "subject-areas": [
        {
            "$": "Immunology and Allergy",
            "@code": "2723"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        }
    ],
    "keywords": [
        "2-dose schedule",
        "Cervarix",
        "Cervical cancer",
        "Human papillomavirus (HPV)"
    ],
    "authors": [
        "Li Min Huang"
    ],
    "citedby-count": 29,
    "ref-count": 35,
    "ref-list": [
        "Human Papillomavirus and Related Diseases Report-World",
        "Global cancer statistics, 2012",
        "Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia",
        "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study",
        "Epidemiologic classification of human papillomavirus types associated with cervical cancer",
        "Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update",
        "The causal relation between human papillomavirus and cervical cancer",
        "Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study",
        "Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: An ongoing cross-sectional study",
        "Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009\u20132013",
        "Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: Case-control study nested within a population based screening programme in Australia",
        "Quadrivalent human papillomavirus vaccine effectiveness: A swedish national cohort study",
        "Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010",
        "Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial",
        "Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years",
        "EUROGIN Conference",
        "Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes",
        "Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 -- conclusions and recommendations.",
        "Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months",
        "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9\u201314 years: Results to month 12 from a randomized trial",
        "Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study",
        "Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study",
        "Eurogin Conference",
        "Immunogenicity of the 9-valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys Vs A 3-Dose Regimen in Women",
        "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial",
        "Sustained efficacy up to 4\u00b75 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial",
        "Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination",
        "Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women",
        "Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial",
        "Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA trials",
        "Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme",
        "Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials",
        "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial",
        "Comparison of the immunogenicity and safety of Cervarix\u2122 and Gardasil\u00ae human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years"
    ],
    "affiliation": [
        {
            "affiliation-city": "Wavre",
            "affilname": "GlaxoSmithKline Pharmaceuticals SA/NV",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Mumbai",
            "affilname": "GlaxoSmithKline Pharmaceuticals Ltd.",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Genoa",
            "affilname": "IRCCS San Martino Polyclinic Hospital",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Cheng Hsin General Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Milan",
            "affilname": "Universit\u00e0 degli Studi di Milano",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hannover",
            "affilname": "Hannover Medical School",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Taoyuan",
            "affilname": "Chang Gung University",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Halifax",
            "affilname": "Dalhousie University",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Padua",
            "affilname": "Universit\u00e0 degli Studi di Padova",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": null,
            "affilname": "Pediatric Office Dr. Med. Michael Horn",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Wurzburg",
            "affilname": "Klinikum W\u00fcrzburg Mitte",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Sudbury",
            "affilname": "Medicor Research Inc",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Sherbrooke",
            "affilname": "Q and T Research",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Wolfsburg",
            "affilname": "Klinikum Wolfsburg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Toronto",
            "affilname": "Manna Research",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Hamburg",
            "affilname": "Facharzt f\u00fcr Frauenheilkunde und Geburtshilfe",
            "affiliation-country": "Germany"
        }
    ],
    "funding": [
        "Pfizer",
        "Sanofi Pasteur",
        "Medizinischen Hochschule Hannover"
    ]
}